atx inhibitor 1

ATX inhibitor 1 is a potent ATX inhibitor with IC50 values of 1.23 nM (FS-3) and 2.18 nM (bis-pNPP).

ATX inhibitor 15 (compound 30) is an indole-based carbamate derivative with a strong inhibitory effect on autotaxin (ATX), demonstrated by an IC50 of 2.17 nM. It effectively inhibits ATX activity in vivo, suppresses the expression of pro-fibrotic genes, and exhibits protective effects in Bleomycin-induced lung fibrosis in mice [1].

ATX inhibitor 10 is a nitrogen-containing heterocyclic compound that is a potent inhibitor of ATX. Among other things, ATX plays a role in causing pathologies including fibrosis, neurodegeneration, arthritis, neuropathic pain, and cancer. ATX inhibitor 10 has shown research potential for ATX-related diseases.

ATX inhibitor 12 is an orally active ATX inhibitor (IC50: 1.72 nM). In C57Bl 6J mice, oral administration of ATX inhibitor 12 at a dose of 60 mg kg was effective in inhibiting structural lung damage and reducing fibrotic lesions.

ATX inhibitor 14, an indole-based carbamate derivative, is a potent inhibitor (IC50: 0.41 nM) of self-adhesive proteins (ATX) and has shown potential for research in fibrosis-related diseases.

ATX inhibitor 19 is a potent inhibitor of ATX (IC50: 156 nM).

ATX inhibitor 16 is a potent ATX inhibitor (IC50: 0.0021 μM) that exhibits a significant anti-proliferative effect on breast cancer cells.

ATX inhibitor 11 is a potent inhibitor of ATX (autotaxin) (IC50: 2.7 nM). ATX inhibitor 11 alleviates the severity of fibrotic tissue and effectively reduces the deposition of α-SMA, a biomarker of fibrosis, in a mouse model of fibrosis. ATX inhibitor 11 can be used to study lung fibrosis.

ATX inhibitor 13 (compound 10c) is an orally active ATX inhibitor (IC50: 3.4 nM) that arrests the cell cycle of RAW264.7 cells in the G2 phase, inhibits cell proliferation and migration, induces apoptosis, and exhibits an inhibitory effect on tumour colony formation.

ATX inhibitor 17, a powerful ATX inhibitor, exhibits an IC50 value of 0.019 µM, demonstrating significant anti-proliferative effects in breast cancer cells.

ATX-IN-1 (compound 35) is an ATX inhibitor with an IC50 of 0.7 nM, demonstrating anti-inflammatory properties. It effectively suppresses the TGF-β Smad pathway and reduces collagen deposition, alleviating fibrosis in a Bleomycin-induced mouse model. This compound also exhibits good oral bioavailability (F=69.5%) and microsomal stability.

Autotaxin-IN-6 (compound 23) is a potent inhibitor of autotaxin (ATX), exhibiting an IC50 of 30 nM, and attenuates cell migration with potential applications in anticancer research [1].

MEY-003, an Autotaxin (ATX) inhibitor, exhibits EC50 values of 460 nM for hATX-β and 1.09 μM for hATX-ɣ (analysis with LPC18:1), demonstrating its potency against these isoforms. It acts non-competitively with a K i of 432 nM, making it suitable for research into diseases where ATX is implicated [1].

Palmitoleoyl 3-carbacyclic phosphatidic acid (3ccPA 16:1) serves as a moderately effective autotaxin (ATX) inhibitor, exhibiting an IC50 value of 620 nM. This compound finds utility in melanoma research[1].

MHC00188 is an allosteric inhibitor of Autotaxin (ATX) with an IC50 of 2.53 μM [1].

MHC02181 is a powerful Autotaxin (ATX) inhibitor, exhibiting an IC50 of 9.41 μM [1].

Anatoxin-a (ATX-a), a neurotoxic alkaloid, functions as an agonist for the nicotinic acetylcholine receptor (nAChR) and as an inhibitor of Acetylcholinesterase (AChE) [1] [2].